BOULDER Enveda Therapeutics Inc. has hired a former top researcher from pharmaceutical giants Eli Lilly & Co. (NYSE: LLY) and AstraZeneca PLC (Nasdaq: AZN) as its chief science officer.
The Boulder company, which does business as Enveda Biosciences, said that it hired Sotirios Karathanasis to lead the company’s pre-clinical research into treatments for liver diseases.
Karathanasis was previously a researcher at Pfizer Inc. (NYSE: PFE) before becoming chief scientific officer of endocrine and cardiovascular research at Eli Lilly Laboratories from 2003 to 2007, and later a vice president of bioscience at AstraZeneca from 2007 to 2019.
He was most recently a vice president of research and development at cardiovascular treatment startup NeoProgen Inc. in Baltimore.
Sotirios-karathanasis
Viswa-colluru
Enveda-biosciences
Neoprogen-inc
Astrazeneca
Pfizer-inc
Enveda-therapeutics-inc
Bizwest-media
Nasdaq
Eli-lilly-co
Enveda-therapeutics
Eli-lilly